Published in Neurology on November 19, 2013
Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. Neurology (2014) 0.78
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. Am J Med Genet A (2016) 0.76
Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care. Ophthalmology (2016) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Reporting results of cancer treatment. Cancer (1981) 28.83
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol (2007) 3.44
Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA (2008) 2.30
Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis (2009) 2.00
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol (1993) 1.58
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol (2006) 1.40
Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist (2012) 1.27
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol (2007) 1.25
Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet (2012) 1.20
Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol (2011) 1.18
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2012) 1.10
Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology (2011) 1.08
Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology (2006) 1.04
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology (2003) 0.98
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer (2012) 0.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. J Neurosurg Pediatr (2010) 2.92
Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol (2015) 2.51
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol (2002) 2.21
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J (2007) 1.63
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res (2008) 1.55
Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis. Brain Pathol (2011) 1.52
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph (2004) 1.50
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Pediatric low-grade gliomas. J Child Neurol (2009) 1.41
Headache as a risk factor for neurovascular events in pediatric brain tumor patients. Neurology (2013) 1.41
Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev Neuropsychol (2006) 1.35
Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol (2012) 1.32
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer (2009) 1.29
Optic pathway gliomas. J Neuroophthalmol (2011) 1.26
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol (2007) 1.25
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol (2010) 1.22
Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol (2011) 1.18
A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers. AIDS Patient Care STDS (2009) 1.18
Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke (2012) 1.18
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis (2012) 1.17
Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol (2011) 1.14
Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer (2007) 1.13
The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder. Dev Disabil Res Rev (2008) 1.13
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol (2008) 1.12
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol (2009) 1.10
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist (2008) 1.09
Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia. Cancer (2006) 1.09
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer (2012) 1.08
Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res (2010) 1.07
Temozolomide in children with progressive low-grade glioma. Neuro Oncol (2007) 1.05
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer (2012) 1.03
Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol (2012) 1.03
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol (2005) 1.03
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res (2008) 1.03
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res (2013) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care (2012) 1.02
Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology (2005) 1.01
Sorafenib and sunitinib. Oncologist (2009) 1.01
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer (2014) 1.01
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci (2013) 1.01
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol (2012) 0.99
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer (2012) 0.98
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res (2006) 0.97
The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell (2012) 0.97
Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med (2008) 0.97
Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. J Neurooncol (2014) 0.96
Analysis of dynamics and propagation of parietal cingulate seizures with secondary mesial temporal involvement. Epilepsy Behav (2008) 0.93
Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics (2003) 0.93
Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett (2012) 0.92
Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol (2012) 0.92
Stressful life events and their relationship to psychological and medical functioning in children and adolescents with HIV infection. J Acquir Immune Defic Syndr (2009) 0.92
Adaptive and maladaptive behavior in children with Smith-Magenis Syndrome. J Autism Dev Disord (2006) 0.92
Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol (2011) 0.92
Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology (2013) 0.92
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol (2007) 0.91
Surgical treatment of brain tumors in infants younger than six months of age and review of the literature. World Neurosurg (2011) 0.90
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer (2014) 0.90
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma (2006) 0.90
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res (2005) 0.89
Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal (2011) 0.89
Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol (2010) 0.89
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A (2010) 0.88
Reduced apoptosis rates in human schwannomas. Brain Pathol (2005) 0.88
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol (2008) 0.87
Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther (2005) 0.87
Alexia without agraphia following biopsy of a left thalamic tumor. Pediatr Neurol (2004) 0.87
Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials. Clin Cancer Res (2011) 0.86
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer (2012) 0.86